Хергенротер Пол Дж. (US),Ботэм Рейчел Си. (US),Фэн Тимоти М. (US),Гилберт Марк Дж. (US),Хендли Майкл К. (US),Тарасов Теодор М. (US),Йоши Авадхут (US),Риггинс Грегори Дж. (US)
申请号：
RU2014139955
公开号：
RU2014139955A
申请日:
2013.03.06
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A composition comprising: (a) a compound of formula (I) :( b) a PAC-1 compound: and (c) a pharmaceutically acceptable diluent, excipient and / or carrier. A composition according to claim 1, characterized in that the carrier comprises water and, optionally, a buffer, cyclodextrin, or a combination thereof. A composition according to claim 2, wherein the cyclodextrin is 2-hydroxypropyl-β-cyclodextrin. A composition according to claim 1, characterized in that the concentration of the compound according to claim I is from about 100 μM to about 1 mm. A composition according to claim 1, characterized in that the concentration of PAC-1 is from about 2 μM to about 50 μM. A composition according to claim 1, characterized in that the concentration of the compound according to claim I is from about 250 μM to about 750 μM, the concentration of PAC-1 is from about 5 μM to about 30 μM. A method for inhibiting the growth and / or proliferation of cancer cells, comprising exposing these cancer cells to an effective amount of a composition of formula 1, which inhibits the growth and / or proliferation of these cancer cells. The method of claim 7, wherein the cancer cells are glioblastoma cells or oligodendroglioma cells. The method of claim 7, wherein the cancer cells are osteosarcoma cells. A method for inducing apoptosis in cancer cells, comprising exposing these cancer cells to an effective amount of a compound of Formula (I): and an effective amount of a PAC-1 compound: characterized in that it leads to the induction of apoptosis in cancer cells. 11. A method according to claim 10, characterized in that the exposure is carried out in vitro. A method according to claim 10, characterized in that the exposure is carried out in vivo. The method according to p. 10, characterized in that the effect on cancer1. Композиция, включающая в себя:(a) соединение формулы (I):(b) соединение PAC-1:и (c) фармацевтически приемлемый разбавитель, наполнитель и/или носитель.2. Композиция по п. 1,
